Surprisingly, ALK inhibition by lorlatinib, when administered as a single agent in neuroblastoma patients, caused weight gain and hypertriglyceridemia [110], an effect observed also in NSCLC patients [121], but not with other ALK inhibitors such as ceritinib [107]. Here, ALK is linked to neuroblastoma.